![]() |
|
|
Vol. 283, Issue 1, 247-258, 1997
Neurological and Urological Diseases Research, Pharmaceutical
Products Division, Abbott Laboratories, Abbott Park, Illinois (M.W.D.,
A.W.B., P.C., K.L.G., J.D.B., M.W.H., N.-H.L., Y.L., J.F.D., S.P.A.),
Department of Pharmacology and Toxicology (J.J.B., M.A.P.) and
Department of Physiology and Endocrinology (W.J.J.),
Medical College of
Georgia and Medical Research Service (J.J.B.,W.J.J.), Veterans
Administration Medical Center, Augusta, Georgia
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine
dihydrochloride], a novel ligand at neuronal nicotinic acetylcholine receptors with reduced adverse effects and improved oral
bioavailability relative to (
)-nicotine, was tested in a variety of
cognitive tests in rats and monkeys. Administered acutely, ABT-089 only marginally improved the spatial discrimination water maze performance of septal-lesioned rats. However, more robust improvement (45% error
reduction on the last training day) was observed when ABT-089 was
administered continuously via subcutaneous osmotic pumps
(minimum effective dose: 1.3 µmol/kg/day). Continuous infusion of
(
)-nicotine produced comparable improvement in the spatial
discrimination water maze performance of septal-lesioned rats, but a
40-fold higher dose of (
)-nicotine was required (62 µmol/kg/day).
Continuous infusion of ABT-089 to aged rats enhanced spatial learning
in a standard Morris water maze, as indexed by spatial bias exhibited during a probe trial conducted after 4 days of training, but not when
they were subsequently trained in a two-platform spatial discrimination
water maze. The compound induced a small impairment in young rats on
the standard water maze, but not on the two-platform task. A probe
trial conducted after additional training in the standard water maze
revealed no age or drug effects. ABT-089 did not affect performance of
either the aged or young rats during inhibitory (passive) avoidance
training. Also, continuous infusion of ABT-089 did not affect responses
to acoustic startle or prepulse inhibition of acoustic startle in
young, aged or septal-lesioned rats and did not affect locomotor
activity in either sham-lesioned or septal-lesioned rats. In monkeys,
acute administration of ABT-089 modestly improved the delayed
matching-to-sample performance of mature, adult monkeys and more
robustly improved performance in aged monkeys. Improved performance in
the aged monkeys was restricted to the longest delay intervals and was
not accompanied by changes in response latencies.
This article has been cited by other articles:
![]() |
V. Parikh, K. Man, M. W. Decker, and M. Sarter Glutamatergic Contributions to Nicotinic Acetylcholine Receptor Agonist-Evoked Cholinergic Transients in the Prefrontal Cortex J. Neurosci., April 2, 2008; 28(14): 3769 - 3780. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. U. Ostrovskaya, M. A. Gruden, N. A. Bobkova, R. D. E. Sewell, T. A. Gudasheva, A. N. Samokhin, S. B. Seredinin, W. Noppe, V. V. Sherstnev, and L. A. Morozova-Roche The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model J Psychopharmacol, August 1, 2007; 21(6): 611 - 619. [Abstract] [PDF] |
||||
![]() |
G. B. Fox, T. A. Esbenshade, J. B. Pan, R. J. Radek, K. M. Krueger, B. B. Yao, K. E. Browman, M. J. Buckley, M. E. Ballard, V. A. Komater, et al. Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 176 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bontempi, K. T. Whelan, V. B. Risbrough, T. S. Rao, J. J. Buccafusco, G. K. Lloyd, and F. Menzaghi SIB-1553A, ({+/-})-4-{[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio}phenol Hydrochloride, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors with Putative Cognitive-Enhancing Properties: Effects on Working and Reference Memory Performances in Aged Rodents and Nonhuman Primates J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 297 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Buccafusco and A. V. Terry Jr. Multiple Central Nervous System Targets for Eliciting Beneficial Effects on Memory and Cognition J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 438 - 446. [Abstract] [Full Text] |
||||
![]() |
J. P. Sullivan, D. Donnelly-Roberts, C. A. Briggs, D. J. Anderson, M. Gopalakrishnan, I. C. Xue, M. Piattoni-Kaplan, E. Molinari, J. E. Campbell, D. G. Mckenna, et al. ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 235 - 246. [Abstract] [Full Text] |
||||